🔴 Femasys is trading 6.76% down in pre-market, possibly reflecting profit-taking

Femasys is trading 6.76% down at $2.76, possibly reflecting profit-taking after recent gains, though no company-specific catalyst has been confirmed.

• No confirmed August 24, 2026 company-specific catalyst has been identified.
• The FDA approved a modular PMA pathway for investigational FemBloc on August 19, a positive regulatory development that previously supported the stock’s advance.
• Broader futures are modestly weaker but do not clearly explain this individual move.